Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.

Joo Y SongAnamarija M PerryAlex F HerreraLu ChenPamela SkrabekMichel R NasrRebecca A OttesenJanet NikowitzVictoria BedellJoyce Murata-CollinsYuping LiChristine McCarthyRaju PillaiJinhui WangXiwei WuJasmine ZainLeslie L PopplewellLarry W KwakAuayporn P NademaneeJoyce C NilandDavid W ScottQiang GongWing C ChanDennis D Weisenburger

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

We propose a practical schema to use genomic variables to risk-stratify patients with GCB DLBCL. This schema provides a promising new approach to identify high-risk patients for new and innovative therapies.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
newly diagnosed
end stage renal disease
ejection fraction
peritoneal dialysis
prognostic factors
gene expression
free survival
genome wide